GH
Guardant Health Inc

4,773
Mkt Cap
$9B
Volume
2.47M
52W High
$72.70
52W Low
$20.82
PE Ratio
-21.56
GH Fundamentals
Price
$72.10
Prev Close
$69.35
Open
$70.28
50D MA
$62.08
Beta
1.56
Avg. Volume
2.66M
EPS (Annual)
-$3.56
P/B
-29.40
Rev/Employee
$365,668.48
Loading...
Loading...
News
all
press releases
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing...
Business Wire·7h ago
News Placeholder
More News
News Placeholder
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
Zacks·9d ago
News Placeholder
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European...
Business Wire·11d ago
News Placeholder
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29...
Business Wire·17d ago
News Placeholder
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Zacks·27d ago
News Placeholder
What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum?
TEM's Q2 net loss narrows sharply, driven by surging genomics revenues, higher gross profits and tighter cost controls.
Zacks·2mo ago
News Placeholder
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Zacks·2mo ago
News Placeholder
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Zacks·2mo ago
News Placeholder
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest GH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.